SCD411 (aflibercept biosimilar)
Stage unconfirmedAflibercept biosimilar for macular degeneration, with exclusive supply agreements in Japan and Europe.
FROM PUBLIC EVENTS · 2026-11-15
Global approvals · expansion Has signed a series of Japanese and European sales agreements for its biosimilar and oral GLP-1 generic. Also seen: Late clinical · capacity
Roles often seen at this stageBD & licensing · Regulatory affairs · Manufacturing & MSAT
A pharmaceutical company selling prescription drugs including ophthalmic products, commercialising an aflibercept biosimilar and an oral GLP-1 generic with overseas partners.
Aflibercept biosimilar for macular degeneration, with exclusive supply agreements in Japan and Europe.
Oral semaglutide generic licensed for 11 European countries.
Signed an exclusive Japanese supply and sales agreement for its aflibercept biosimilar with a new partner.
Disclosed a licensing agreement for its oral GLP-1 generic covering 11 European countries.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.